3Walker J, Robinson J, Stewart J, et al. Does enteric- coated aspirin result in lower incidence of gastrointestinal comlications compared to normal aspirin?[J]. Interact Cardiovasc Thorac Surg, 2007, 6(4): 519-522.
4Cole AT, Hudson N, Liew LC, et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?[J]. Aliment Pharmacol Ther, 1999, 13(2): 187-193.
5Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosallesions[J]. Aliment Pharmacol Ther, 1999, 13(8): 1109-1114.
6Blondon H, Barbier JP, Mah6 I, et al.Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formulation vs. regular formulation in healty volunteers[J]. Fundam clin pharmacol, 2000, 14(2): 155-157.
7Hawthorne AB, Mahida YR, Cole AT, et al. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis[J]. Br J Clin Pharmacol, 1991, 32(1): 77-83.
8Petroski D. Endoscopic comparison of three aspirin preparations and placebo[J]. Clin ther, 1993, 15(2): 314-320.
9Peters R J, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study[J]. Circulation, 2003, 14(108): 1682-1687.
10Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin- associated major upper-gastrointestinal bleeding with enteric- coated or buffered product[J]. Lancet, 1996, 348(9039): 1413 1416.
